Literature DB >> 18950670

A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Jane Gidudu1, Katrin S Kohl, Scott Halperin, Sandra Jo Hammer, Paul T Heath, Renald Hennig, Bernard Hoet, Edward Rothstein, Anne Schuind, Frederick Varricchio, Wikke Walop.   

Abstract

The need for developing a case definition and guidelines for a local reaction at or near the injection site, methods for the development of the case definition and guidelines as an adverse event following immunization as well as the rationale for selected decisions about the case definition for a local reaction at or near the injection site are explained in the Preamble section. The case definition is structured in 2 levels of diagnostic certainty: level 1 includes any description of morphological or physiological change at or near the injection site that is described or identified by a healthcare provider. Level 2 is any description of morphological or physiological change at or near injection site that is described by any other person. In Guidelines section, the working group recommends to enable meaningful and standardized data collection, analysis, and presentation of information about a local reaction at or near the injection site. However, implementation of all guidelines might not be possible in all settings. The availability of information may vary depending upon resources, geographic region, and whether the source of information is a prospectively designed clinical trial, a post-marketing surveillance or epidemiologic study, or an individual report of a local reaction at injection site.

Entities:  

Mesh:

Year:  2008        PMID: 18950670     DOI: 10.1016/j.vaccine.2008.10.006

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.

Authors:  Karina Takesaki Miyaji; André Machado Luiz; Amanda Nazareth Lara; Tania do Socorro Souza Chaves; Roberta de Oliveira Piorelli; Marta Heloisa Lopes; Ana Marli Christovam Sartori
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

2.  The use of natural language processing to identify Tdap-related local reactions at five health care systems in the Vaccine Safety Datalink.

Authors:  Chengyi Zheng; Wei Yu; Fagen Xie; Wansu Chen; Cheryl Mercado; Lina S Sy; Lei Qian; Sungching Glenn; Gina Lee; Hung Fu Tseng; Jonathan Duffy; Lisa A Jackson; Matthew F Daley; Brad Crane; Huong Q McLean; Steven J Jacobsen
Journal:  Int J Med Inform       Date:  2019-04-13       Impact factor: 4.046

3.  Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.

Authors:  Silvia Perez-Vilar; Graça M Dores; Paige L Marquez; Carmen S Ng; Maria V Cano; Anuja Rastogi; Lucia Lee; John R Su; Jonathan Duffy
Journal:  Vaccine       Date:  2021-12-07       Impact factor: 3.641

4.  Template protocol for clinical trials investigating vaccines--focus on safety elements.

Authors:  Jan Bonhoeffer; Egeruan B Imoukhuede; Grace Aldrovandi; Novilia S Bachtiar; Eng-Soon Chan; Soju Chang; Robert T Chen; Rohini Fernandopulle; Karen L Goldenthal; James D Heffelfinger; Shah Hossain; Indira Jevaji; Ali Khamesipour; Sonali Kochhar; Mamodikoe Makhene; Elissa Malkin; David Nalin; Rebecca Prevots; Ranjan Ramasamy; Sarah Sellers; Johan Vekemans; Kenneth B Walker; Pam Wilson; Virginia Wong; Khalequz Zaman; Ulrich Heininger
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

5.  Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women.

Authors:  Christine E Jones; Flor M Munoz; Hans M L Spiegel; Ulrich Heininger; Patrick L F Zuber; Kathryn M Edwards; Philipp Lambach; Pieter Neels; Katrin S Kohl; Jane Gidudu; Steven Hirschfeld; James M Oleske; Najwa Khuri-Bulos; Jorgen Bauwens; Linda O Eckert; Sonali Kochhar; Jan Bonhoeffer; Paul T Heath
Journal:  Vaccine       Date:  2016-07-29       Impact factor: 3.641

6.  Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018.

Authors:  Jonathan Duffy; Paige Marquez; Graça M Dores; Carmen Ng; John Su; Maria Cano; Silvia Perez-Vilar
Journal:  Open Forum Infect Dis       Date:  2020-10-27       Impact factor: 3.835

7.  A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.

Authors:  Sabine Bélard; Saadou Issifou; Aurore B Hounkpatin; Frieder Schaumburg; Ulysse Ateba Ngoa; Meral Esen; Rolf Fendel; Pablo Martinez de Salazar; Raymund E Mürbeth; Paul Milligan; Nathalie Imbault; Egeruan Babatunde Imoukhuede; Michael Theisen; Søren Jepsen; Ramadhani A Noor; Brenda Okech; Peter G Kremsner; Benjamin Mordmüller
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

8.  Needle size for vaccination procedures in children and adolescents.

Authors:  Paul V Beirne; Sarah Hennessy; Sharon L Cadogan; Frances Shiely; Tony Fitzgerald; Fiona MacLeod
Journal:  Cochrane Database Syst Rev       Date:  2018-08-09

9.  Safety of a Trivalent Inactivated Influenza Vaccine in Health Care Workers in Kurdistan Province, Western Iran; A Longitudinal Follow-up Study.

Authors:  Jafar Soltani; Mohamad Jamil Amjadi
Journal:  Iran J Med Sci       Date:  2014-03

Review 10.  Vaccination in elite athletes.

Authors:  Barbara C Gärtner; Tim Meyer
Journal:  Sports Med       Date:  2014-10       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.